Celldex Therapeutics, Inc.
CLDX
$21.88
-$0.05-0.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -30.25% | 24.49% | 1.99% | 128.55% | 155.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.25% | 24.49% | 1.99% | 128.55% | 155.05% |
| Cost of Revenue | 46.00% | 50.16% | 38.59% | 33.08% | 39.77% |
| Gross Profit | -50.95% | -51.49% | -40.86% | -29.16% | -35.79% |
| SG&A Expenses | 17.70% | 20.64% | 24.69% | 29.41% | 30.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.18% | 43.85% | 35.70% | 32.33% | 37.81% |
| Operating Income | -43.76% | -44.63% | -37.34% | -29.21% | -34.67% |
| Income Before Tax | -32.88% | -23.45% | -11.62% | -23.65% | -32.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.88% | -23.45% | -11.62% | -23.65% | -32.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.88% | -23.45% | -11.62% | -23.65% | -32.78% |
| EBIT | -43.76% | -44.63% | -37.34% | -29.21% | -34.67% |
| EBITDA | -44.45% | -45.42% | -38.02% | -29.71% | -35.26% |
| EPS Basic | -9.70% | 5.14% | 15.95% | 2.69% | -14.24% |
| Normalized Basic EPS | -20.23% | -3.61% | 8.39% | 11.79% | -4.24% |
| EPS Diluted | -9.70% | 5.29% | 16.08% | 3.00% | -13.84% |
| Normalized Diluted EPS | -20.23% | -3.61% | 8.39% | 11.79% | -4.24% |
| Average Basic Shares Outstanding | 18.40% | 29.03% | 32.92% | 28.78% | 18.92% |
| Average Diluted Shares Outstanding | 18.40% | 29.03% | 32.92% | 28.78% | 18.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |